Simon Crabb and Petros Grivas on the most interesting trials presented at ASCO GU 2022.

Simon Crabb and Petros Grivas on the most interesting trials presented at ASCO GU 2022.

Urothelial carcinoma trial data presented at ASCO GU 2022Подробнее

Urothelial carcinoma trial data presented at ASCO GU 2022

Key trials in bladder cancer from ASCO GU 2022Подробнее

Key trials in bladder cancer from ASCO GU 2022

The Uromigos: Bladder Cancer Buzzer RoundПодробнее

The Uromigos: Bladder Cancer Buzzer Round

ASCO GU 2022Подробнее

ASCO GU 2022

Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018Подробнее

Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018

Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancerПодробнее

Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancer

ESMO Expert Report on antibody drug conjugates in the management of urothelial cancer @ASCO GU 2022Подробнее

ESMO Expert Report on antibody drug conjugates in the management of urothelial cancer @ASCO GU 2022

ATLANTIS points to maintenance benefit of rucaparib in mUC | Simon CrabbПодробнее

ATLANTIS points to maintenance benefit of rucaparib in mUC | Simon Crabb

ICAHO20 - ASCO Direct™ Highlights - Genito Urinary Cancers - Dr. Petros GrivasПодробнее

ICAHO20 - ASCO Direct™ Highlights - Genito Urinary Cancers - Dr. Petros Grivas

SCCA’s Dr. Petros Grivas spoke on phase III JAVELIN Bladder 100 TrialПодробнее

SCCA’s Dr. Petros Grivas spoke on phase III JAVELIN Bladder 100 Trial

Petros Grivas, MD | Key Takeaways on Genitourinary Cancer at 2019 ASCO Direct Highlights DenverПодробнее

Petros Grivas, MD | Key Takeaways on Genitourinary Cancer at 2019 ASCO Direct Highlights Denver

Additional insights from JAVELIN Bladder 100 | Petros GrivasПодробнее

Additional insights from JAVELIN Bladder 100 | Petros Grivas

The AURORA trialПодробнее

The AURORA trial

GU ASCO Symposium 2022 SummaryПодробнее

GU ASCO Symposium 2022 Summary